Matt Larew
Stock Analyst at William Blair
(0.26)
# 4,241
Out of 4,944 analysts
13
Total ratings
28.57%
Success rate
-30.25%
Average return
Main Sectors:
Stocks Rated by Matt Larew
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MXCT MaxCyte | Downgrades: Market Perform | n/a | $1.38 | - | 2 | Aug 7, 2025 | |
| MRVI Maravai LifeSciences Holdings | Downgrades: Market Perform | n/a | $2.75 | - | 1 | Nov 8, 2024 | |
| AMED Amedisys | Downgrades: Market Perform | n/a | $100.98 | - | 1 | Jul 1, 2024 | |
| DNA Ginkgo Bioworks Holdings | Downgrades: Underperform | n/a | $13.26 | - | 3 | May 10, 2024 | |
| ATR AptarGroup | Upgrades: Outperform | n/a | $141.43 | - | 1 | Apr 29, 2024 | |
| TECH Bio-Techne | Initiates: Outperform | n/a | $54.71 | - | 1 | Aug 28, 2023 | |
| AVTR Avantor | Downgrades: Market Perform | n/a | $13.07 | - | 1 | Jul 31, 2023 | |
| INNV InnovAge Holding | Downgrades: Market Perform | n/a | $3.74 | - | 2 | Sep 22, 2021 | |
| TWST Twist Bioscience | Initiates: Outperform | n/a | $28.65 | - | 1 | Jun 29, 2021 |
MaxCyte
Aug 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.38
Upside: -
Maravai LifeSciences Holdings
Nov 8, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.75
Upside: -
Amedisys
Jul 1, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $100.98
Upside: -
Ginkgo Bioworks Holdings
May 10, 2024
Downgrades: Underperform
Price Target: n/a
Current: $13.26
Upside: -
AptarGroup
Apr 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $141.43
Upside: -
Bio-Techne
Aug 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $54.71
Upside: -
Avantor
Jul 31, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $13.07
Upside: -
InnovAge Holding
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $3.74
Upside: -
Twist Bioscience
Jun 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $28.65
Upside: -